Inventiva S.A. (NASDAQ:IVA - Get Free Report) shot up 3.2% during mid-day trading on Friday . The stock traded as high as $3.90 and last traded at $3.89. 5,289 shares traded hands during trading, a decline of 92% from the average session volume of 62,748 shares. The stock had previously closed at $3.77.
Analyst Upgrades and Downgrades
IVA has been the topic of several analyst reports. Guggenheim lowered their target price on Inventiva from $12.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, April 4th. HC Wainwright reissued a "buy" rating and set a $13.00 price target on shares of Inventiva in a report on Friday, March 28th. Finally, TD Cowen assumed coverage on shares of Inventiva in a research note on Friday, February 21st. They set a "buy" rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.40.
Check Out Our Latest Report on Inventiva
Inventiva Stock Performance
The business has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $2.70.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Read More
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
